Merus (NASDAQ:MRUS) had its price objective upped by Citigroup from $31.00 to $38.00 in a report released on Monday, The Fly reports. The firm currently has a buy rating on the biotechnology company’s stock.
Several other equities analysts also recently commented on the company. HC Wainwright reiterated a buy rating and issued a $30.00 price objective on shares of Merus in a research note on Monday, August 9th. Zacks Investment Research downgraded Merus from a hold rating to a sell rating in a research report on Wednesday, August 11th. Roth Capital increased their target price on Merus from $32.00 to $40.00 and gave the stock a buy rating in a research report on Thursday, October 7th. Finally, SVB Leerink increased their target price on Merus from $33.00 to $45.00 and gave the stock an outperform rating in a research report on Friday, October 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of Buy and a consensus target price of $34.17.
Merus stock opened at $31.14 on Monday. Merus has a 12 month low of $11.19 and a 12 month high of $31.80. The business’s 50 day simple moving average is $23.90 and its 200 day simple moving average is $22.02. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -11.45 and a beta of 0.77.
In other Merus news, SVP Kruif John De sold 2,787 shares of the firm’s stock in a transaction dated Thursday, August 12th. The shares were sold at an average price of $19.34, for a total value of $53,900.58. Following the completion of the sale, the senior vice president now directly owns 15,830 shares in the company, valued at $306,152.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Bvf Partners L. P/Il sold 985,447 shares of Merus stock in a transaction that occurred on Thursday, October 7th. The shares were sold at an average price of $27.53, for a total transaction of $27,129,355.91. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Macquarie Group Ltd. bought a new stake in shares of Merus during the second quarter valued at approximately $27,000. UBS Group AG increased its position in shares of Merus by 214.8% during the first quarter. UBS Group AG now owns 2,899 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 1,978 shares in the last quarter. Citigroup Inc. increased its position in shares of Merus by 3,238.6% during the second quarter. Citigroup Inc. now owns 7,779 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 7,546 shares in the last quarter. Jump Financial LLC bought a new stake in shares of Merus during the second quarter valued at approximately $202,000. Finally, Virtus ETF Advisers LLC bought a new stake in shares of Merus during the second quarter valued at approximately $208,000. 69.61% of the stock is owned by institutional investors.
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.
See Also: Debt-To-Equity Ratio
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.